SCHEMBL2423583

SCHEMBL2423583

CC(O)Cc1c(Cl)cccc1C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.44
CTSS P25774 3/20 0.38
RORC P51449 3/20 0.37
PDE2A O00408 1/20 0.37
NOTUM Q6P988 1/20 0.36
CTSK P43235 2/20 0.36
PTGS2 P35354 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
HSD11B1 P28845 1/20 0.36
TYK2 P29597 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
AKR1B1 P15121 1/20 0.35
PIEZO1 Q92508 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19443758 0.88 P2RX7 (0.45) P2RX7CTSSRORCCTSKPTGS2
SCHEMBL9248083 0.83 HPGD (0.36) P2RX7L3MBTL1AKR1B1
SCHEMBL18419819 0.83 P2RX7 (0.41) P2RX7CTSSRORCCTSKSLC6A2
SCHEMBL2426412 0.83 AKR1B1 (0.43) SLC6A2SLC6A4L3MBTL1AKR1B1GAA
SCHEMBL15083012 0.83 AKR1B1 (0.43) SLC6A2SLC6A4L3MBTL1AKR1B1GAA
Hydrochloric Acid SCHEMBL9253661 0.82 HPGD (0.35) L3MBTL1AKR1B1
SCHEMBL2427582 0.81 SLC6A2 (0.46) P2RX7PDE2APTGS2SLC6A2SLC6A4
SCHEMBL2428955 0.79 GAA (0.53) L3MBTL1GAA
SCHEMBL16939396 0.78 P2RX7 (0.41) P2RX7CTSSRORCCTSKPTGS2
SCHEMBL12812210 0.78 TAAR1 (0.41) P2RX7RORCPTGS2TYK2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2265616-B1 FURO-AND THIENO[3,2-C]PYRIDINES OSI PHARM INC (US) 2013-11-20 EP disclosed
US-8022206-B2 Furo[3,2-C]pyridines OSI Pharmaceuticals, LLC (US) 2011-09-20 US disclosed
US-8022206-B2 Furo[3,2-C]pyridines OSI Pharmaceuticals, LLC (US) 2011-09-20 US disclosed
US-8022206-B2 Furo[3,2-C]pyridines OSI Pharmaceuticals, LLC (US) 2011-09-20 US disclosed
EP-2265616-A1 FURO-AND THIENO[3,2-C]PYRIDINES OSI Pharmaceuticals, Inc. (US) 2010-12-29 EP disclosed
WO-2009100282-A1 FURO-AND THIENO[3,2-C] PYRIDINES OSI PHARMACEUTICALS, INC. (US) 2009-08-13 WO disclosed
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines RET, MET, ERBB2 P2RX7 1479/4885CTSS 2853/4885RORC 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.